Studies toward new anti-cancer strategies based on alpha-mannosidase inhibition.
Changes in the glycosylation pattern of cellular glycoproteins constitute a hallmark in human cancer and influence tumor progression, suggesting that inhibitors of selected glycosidases may control cancer progression. Following the studies on swainsonine, a natural inhibitor of Golgi alpha-mannosidase II, which highlighted the inhibition of cellular mannosidases as a potential innovative approach for the treatment of cancer, several dihydroxylated pyrrolidines and analogues were developed as new potent inhibitors of alpha-mannosidases II able to induce antiproliferative effects in human cancer cells.
Institute of Chemical Sciences and Engineering, Ecole Polytechnique Fédérale de Lausanne, Batochime, CH-1015 Lausanne, Switzerland. Sandrine.Gerber@epfl.ch
Sandrine
S
Gerber-Lemaire
Lucienne
L
Juillerat-Jeanneret
D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D049109:Cell Proliferation / Q000187:drug effects; D006031:Glycosylation; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology* / Q000473:pathology; D017026:Swainsonine / Q000627:therapeutic use*; D043323:alpha-Mannosidase / Q000037:antagonists & inhibitors* / Q000378:metabolism
D000972:Antineoplastic Agents, Phytogenic; D043323:alpha-Mannosidase; D017026:Swainsonine